Top in GI: Entyvio, coagulopathy of COVID-19

A recent study showed that Entyvio remained effective 2 years after patients with inflammatory bowel disease reduced their dosing frequency from every 4 weeks to every 8 weeks. It was the top story in gastroenterology last week.

Another top story was about a presentation during The Liver Meeting Digital Experience on an association between COVID-19-related coagulopathy and liver injury.

Read these and more top stories in gastroenterology below:

Entyvio shows high patient persistence after dose frequency reduction

Patients with inflammatory bowel disease who reduced the frequency of Entyvio (vedolizumab, Takeda) dosing showed high persistence and low rates of relapse, according to study results. Read more.

Coagulopathy of COVID-19 correlates with liver injury

Researchers identified a correlation between the coagulopathy of COVID-19 driven by endothelial Factor VIII and liver injury. Read more.

VIDEO: Seladelpar safe, well-tolerated in patients with primary biliary cholangitis

In this video, Gideon Hirschfield, FRCP, PhD, from the Toronto Centre for Liver Disease, University of Toronto, discusses results from the ENHANCE study of seladelpar (CymBay Therapeutics) for treating patients with primary biliary cholangitis. Read more.

Helmsley awards $4.7 million for Crohn's diet therapy research

The Leona M. and Harry B. Helmsley Charitable Trust awarded nearly $4.7 million to fund three studies designed to explore dietary interventions for Crohn’s disease, according to a press release. Read more.

Global HBV mortality burden remains high

Despite a global initiative to reduce hepatitis B mortality, few of the countries with the highest burden are on track to meet elimination targets, according to research presented at the Liver Meeting Digital Experience. Read more.